Long-term biological variability of galectin-3 after heart transplantation

Abstract

The concentrations of galectin-3 in patients followed 12 months after HTx fluctuated around the homeostatic point, with CVi of approximately 28%. RCVs of +116% (log-normal increase) and -54% (log-normal decrease) mean that the concentration of galectin-3 would need to approximately double or decrease by half to indicate a new process.

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)

“…Galectin-3 analyzed 10 days following HT displayed an association with heart function assessed 1 year after HT ( 92 ). Furthermore, galectin-3 fluctuated in patients followed up for 12 months after HT, and a novel process was indicated when galectin-3 increased by double or decreased by one-half compared to the baseline level ( 93 ). Contrastingly, Grupper et al ( 94 ) reported that although the galectin-3 expression level increased despite HT, and was associated with renal dysfunction, it was not associated with the presence of myocyte hypertrophy and interstitial fibrosis post HT ( 94 ).…”